<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>payload diversification &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/payload-diversification/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 19 Oct 2026 14:21:40 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>payload diversification &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Antibody–Drug Conjugates Reshape Solid Tumor Therapy Amid Safety and Target Challenges</title>
		<link>https://bioengineer.org/antibody-drug-conjugates-reshape-solid-tumor-therapy-amid-safety-and-target-challenges/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Mon, 19 Oct 2026 14:21:40 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[antibody-drug conjugates]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[bispecific antibodies]]></category>
		<category><![CDATA[Cancer immunotherapy]]></category>
		<category><![CDATA[China oncology pipeline]]></category>
		<category><![CDATA[drug resistance]]></category>
		<category><![CDATA[HER2]]></category>
		<category><![CDATA[interstitial lung disease]]></category>
		<category><![CDATA[ocular toxicity]]></category>
		<category><![CDATA[payload diversification]]></category>
		<category><![CDATA[solid tumors]]></category>
		<category><![CDATA[targeted therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=437995</guid>

					<description><![CDATA[A new review in Holistic Integrative Oncology charts the rapid rise of antibody–drug conjugates in solid tumors while detailing the target scarcity, biomarker gaps, and ocular and lung toxicities that still limit them.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">437995</post-id>	</item>
	</channel>
</rss>
